The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer


Altaner S., YÖRÜK Y., Tokatli F., KOÇAK Z., TOSUN B., GÜREŞCİ S., ...Daha Fazla

Tumori, cilt.92, sa.4, ss.323-326, 2006 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 92 Sayı: 4
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1177/030089160609200411
  • Dergi Adı: Tumori
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.323-326
  • Anahtar Kelimeler: Adenocarcinoma, Adenosquamous carcinoma, Lung, Prognosis, TTF-1
  • Trakya Üniversitesi Adresli: Evet

Özet

Aims and background: Thyroid transcription factor (TTF-1) is a tissue-specific transcription factor expressed in the epithelial cells of thyroid and lung. The aim of this study was to evaluate the relationship between the expression of TTF-1 and clinico-pathological parameters in pulmonary adenocarcinoma and adenosquamous carcinoma. Methods: Resection material of pneumonectomies and lobectomies of 39 patients was retrospectively examined. Twenty-eight patients were diagnosed with adenocarcinoma and 11 with adenosquamous carcinoma. Tumors were classified into 3 groups: a strongly positive group (++) with ‡50% tumor cells positive for TTF-1; a weakly positive group (+) with 1-49% positive tumor cells; and a negative group (-) with less than 1% or no positive tumor cells. Analysis was performed with Kaplan-Meier estimates and log-rank tests. Results: Staining for TTF-1 was negative in 10 cases. There was focal staining in 9 cases, while there was diffuse staining in 20 (51%) cases out of 39, and 15 (75%) of these were adenocarcinomas. There was a statistically significant association between TTF-1 and lymph node metastases (P = 0.029). No relationship was found between TTF-1 positivity and disease-free and overall survival. Conclusions: TTF-1 expression may be a predictor of lymph node metastases. Additional work in a larger group of patients is needed to better assess the utility of this marker.